Targeted therapy of urological tumours. Experimental field or established therapeutic approach?

被引：9

作者：

Kramer, M. W. ^{[1
]}

Krege, S. ^{[2
]}

Peters, I. ^{[1
]}

Merseburger, A. S. ^{[1
]}

Kuczyk, M. A. ^{[1
]}

机构：

[1] Hannover Med Sch, Klin Urol & Urol Onkol, D-30625 Hannover, Germany

[2] Krankenhaus Maria Hilf, Abt Urol & Kinderurol, Krefeld, Germany

来源：

UROLOGE | 2010年 / 49卷 / 10期

关键词：

Urological cancer; Targeted therapy; Current status; EPIDERMAL-GROWTH-FACTOR; TRANSITIONAL-CELL CARCINOMA; INTERFERON-ALPHA; DOSE CHEMOTHERAPY; FACTOR RECEPTOR; PHASE-II; EXPRESSION; BLADDER; SORAFENIB; SUNITINIB;

D O I：

10.1007/s00120-010-2397-2

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

Unlike conventional systemic chemotherapies, the aim of targeted therapeutic approaches is not to address general mechanisms involved in cellular replication. In contrast, they aim at such regulatory pathways that have been identified to be involved in the progression of human malignant disease. Whereas the application of targeted therapeutic modalities is well established for the treatment of metastatic renal cell cancer, only very few data on their clinical efficacy during the treatment of other urological tumours such as prostate and bladder cancer are currently available, The aim of this paper is to reflect on the current status regarding the relevance of targeted therapeutic approaches during the treatment of urological cancers of different origin.

引用

页码：1260 / 1265

页数：6

共 43 条

[1] Final analysis of a phase II trial using sorafenib for metastatic castration-resistant prostate cancer [J].

Aragon-Ching, Jeanny B. ;

Jain, Lokesh ;

Gulley, James L. ;

Arlen, Philip M. ;

Wright, John J. ;

Steinberg, Seth M. ;

Draper, David ;

Venitz, Juergen ;

Jones, Elizabeth ;

Chen, Clara C. ;

Figg, William D. ;

Dahut, William L. .

BJU INTERNATIONAL, 2009, 103 (12) :1636-1640

[2] Hand-Foot Skin Reaction Increases with Cumulative Sorafenib Dose and with Combination Anti-Vascular Endothelial Growth Factor Therapy [J].

Azad, Nilofer S. ;

Aragon-Ching, Jeanny B. ;

Dahut, William L. ;

Gutierrez, Martin ;

Figg, William D. ;

Jain, Lokesh ;

Steinberg, Seth M. ;

Turner, Maria L. ;

Kohn, Elise C. ;

Kong, Heidi H. .

CLINICAL CANCER RESEARCH, 2009, 15 (04) :1411-1416

[3]

BELLMUNT J, 2010, J CLIN ONCOL, V28, P351

[4] High-dose versus conventional-dose chemotherapy as first-salvage treatment in patients with non-seminomatous germ-cell tumors: a matched-pair analysis [J].

Beyer, J ;

Stenning, S ;

Gerl, A ;

Fossa, S ;

Siegert, W .

ANNALS OF ONCOLOGY, 2002, 13 (04) :599-605

[5] Survival after an Antiangiogenetic Therapy and Surgery in a Wide Spread Growing Teratoma Originating from a Testicular Mixed Malignant Germ Cell Tumor [J].

Calaminus, G. ;

Schneider, D. T. ;

Weissbach, L. ;

Schoenberger, S. ;

Okpanyi, V. ;

Leuschner, I. ;

Poremba, C. ;

Goebel, U. .

KLINISCHE PADIATRIE, 2009, 221 (03) :136-140

[6]

CHIACHI L, 2007, BJU INT, V101, P795

[7]

Chow NH, 1997, ANTICANCER RES, V17, P1293

[8] A phase II clinical trial of sorafenib in androgen-independent prostate cancer [J].

Dahut, William L. ;

Scripture, Charity ;

Posadas, Edwin ;

Jain, Lokesh ;

Gulley, James L. ;

Arlen, Philip M. ;

Wright, John J. ;

Yu, Yunkai ;

Cao, Liang ;

Steinberg, Seth M. ;

Aragon-Ching, Jeanny B. ;

Venitz, Juergen ;

Jones, Elizabeth ;

Chen, Clara C. ;

Figg, William D. .

CLINICAL CANCER RESEARCH, 2008, 14 (01) :209-214

[9] High-dose chemotherapy and stem-cell rescue for metastatic germ-cell tumors [J].

Einhorn, Lawrence H. ;

Williams, Stephen D. ;

Chamness, Amy ;

Brames, Mary J. ;

Perkins, Susan M. ;

Abonour, Rafat .

NEW ENGLAND JOURNAL OF MEDICINE, 2007, 357 (04) :340-348

[10] Phase II study of imatinib mesylate in chemotherapy refractory germ cell tumors expressing KIT [J].

Einhorn, LH ;

Brames, MJ ;

Heinrich, MC ;

Corless, CL ;

Madani, A .

AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2006, 29 (01) :12-13

← 1 2 3 4 5 →